Latest news with #Next-GenerationSequencing
&w=3840&q=100)
Business Standard
7 days ago
- Health
- Business Standard
Could gene therapy end thalassemia? China's breakthrough sparks hope
Can a single shot rewrite a child's genetic fate? In a groundbreaking trial, doctors in China have used gene therapy to successfully treat children with thalassemia, a life-threatening inherited blood disorder that has long burdened families with frequent transfusions and lifelong medical care. As reported by media reports, one-time treatment using gene-edited stem cells has enabled multiple children to live transfusion-free for over a year. The promise is immense as it might offer a potential cure for a disease that affects millions across the globe. What is thalassemia and how does it impact the body? According to the Cleveland Clinic, an American nonprofit academic medical center based in Cleveland, Ohio, thalassemia is a genetic blood disorder that affects the body's ability to produce healthy haemoglobin, the oxygen-carrying component of red blood cells. This results in chronic anemia, fatigue, developmental delays, bone deformities, and in severe cases, life-threatening complications. US Centers for Disease Control and Prevention (CDC) classifies Thalassemia based on which part of the haemoglobin molecule is affected, alpha or beta, and the severity of the condition, described as trait, intermedia, or major. Thalassemia types are classified based on which part of the hemoglobin molecule is affected—alpha or beta—and the severity of the condition, described as trait, intermedia, or major. Hemoglobin, responsible for carrying oxygen throughout the body, consists of alpha and beta protein chains. When the body can't produce enough of either, it leads to alpha or beta thalassemia, resulting in reduced hemoglobin levels and varying degrees of anemia. According to severity: How common is thalassemia in India and how is it diagnosed? According to a new study by Metropolis Healthcare, an Indian multinational diagnostic, more than 1 in 4 Indian children clinically suspected of inherited blood disorders found positive. The study highlighted that over 51 per cent of affected children were under age 3, reinforcing the urgent need for prenatal and early childhood screening. 'Our findings reveal an urgent public health concern. Early detection through prenatal and newborn screening can dramatically alter disease outcomes,' said Dr Smita Sudke, Chief of Laboratory, Metropolis Healthcare. Advanced molecular techniques like Next-Generation Sequencing (NGS), Gap-PCR, and Sanger sequencing now make it possible to detect mutations with high precision, even before symptoms appear. 'NGS is a game-changer for identifying rare and novel mutations. It helps decode unexplained symptoms and enables early, even pre-symptomatic, diagnosis,' said Dr Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare. Metropolis' earlier study of 65,779 cases across revealed how modern DNA sequencing is improving diagnosis and disease classification, especially for beta-thalassemia. Why premarital and prenatal screening matter in thalassemia Despite the high burden, premarital screening remains rare in India due to social stigma. However, antenatal testing is gaining ground in high-risk groups. Doctors stress the importance of screening both partners before pregnancy. If both are carriers, there's a 25 per cent chance of the child having thalassemia major, a severe, lifelong condition. How is thalassemia treated in India today? Standard treatment in India includes: Regular blood transfusions Iron chelation therapy to remove excess iron Bone marrow transplant (BMT): A potential cure if a matched donor is available Gene therapy: Experimental in India, but now a realistic hope According to Dr Rahul Bhargava, Principal Director & Chief of BMT at Fortis Memorial Research Institute, 'A matched bone marrow transplant offers a curative option. But gene therapy could transform how we approach thalassemia treatment in the future.' What is the cost burden of thalassemia care in India? Annual cost of treatment ranges between ₹1.5–4 lakhs for transfusions and medications Bone Marrow Transplant costs ₹10–25 lakhs (some public hospitals subsidise) Gene therapy is currently unavailable in India and is expected to be expensive initially Can thalassemia be prevented through screening and awareness? According to experts, yes, prevention is possible through: Carrier screening Prenatal testing Genetic counseling Dr Sudke adds, 'We must integrate genetic screening into routine maternal and child health programs. It's the most effective way to reduce the future burden.' What does the gene therapy success in China mean for India?
New Indian Express
7 days ago
- Health
- New Indian Express
TN to set up centres of excellence for genetic disorder prevention in Coimbatore, Madurai
COIMBATORE: The state health department with the support of National Health Mission (NHM) is preparing to launch Centers of Excellence for the prevention and management of genetic disorders in Coimbatore and Madurai, following the footsteps of Chennai. These centers aim to facilitate genetic research and laboratory tests for conditions such as inborn errors of metabolism and immune deficiencies. Construction of the buildings and procurement of high-value machinery are currently underway, said officials and added that 50% of the work has been completed. Recognising that genetic disorders are a major cause of Infant Mortality Rate (IMR) and Under-Five Mortality Rate (U5MR), the state government has allocated Rs 8.19 crore to establish two new Centres of Excellence in Coimbatore and Madurai, said officials. "The center is already operational at the Institute of Child Health and Hospital for Children (ICH) in Chennai. Efforts to launch similar centers at government medical college hospitals in Coimbatore and Madurai are in progress," said Expert Advisor for Child Health, National Health Mission, Tamil Nadu S Srinivasan. The centers will specialise in a variety of genetic disorders, including hemoglobinopathies like thalassemia and sickle cell anemia, chromosomal disorders, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), other neuromuscular disorders, lysosomal storage diseases (LSD), mucopolysaccharidosis (MPS), congenital adrenal hyperplasia, congenital hypothyroidism, glucose-6-phosphate dehydrogenase (G-6PD) deficiency, and cystic fibrosis, as outlined in the government order. "We have acquired expensive machinery such as Tandem Mass Spectrometry (TMS) and Next-Generation Sequencing (NGS) for genetic testing, among other equipments, at the ICH in Chennai. With this laboratory, we can screen patients with genetic disorders, diagnose their conditions, and explore potential solutions. For example, inborn errors of metabolism (IEM) are rare genetic conditions that impair the body's ability to convert food into energy due to enzyme defects. Using TMS, we can screen and diagnose IEMs," Dr Srinivasan added.
India Today
22-05-2025
- Health
- India Today
India's hidden health crisis: Genetic blood disorders plague children under 12
India is facing a hidden health crisis among children: the alarming rate of inherited blood data from Metropolis Healthcare, a diagnostic laboratory chain, has found that more than 1 in 4 children from 0 to 12 suspected of having a blood disorder were found to carry inherited haemoglobin findings are based on a three-year study conducted between 2021 and The study screened nearly 20,000 children who showed signs of haemoglobinopathies, a group of inherited conditions that affect red blood cells and can lead to chronic anaemia, fatigue, delayed growth, and vulnerability to 28.4% of these children tested positive for a haemoglobin disorder, raising serious questions about the reach and effectiveness of India's paediatric and maternal health two most common conditions identified were beta-thalassaemia trait (38.7%) and sickle cell disease (30%). Thalassemia. Beta-thalassaemia affects the body's ability to produce enough red blood cells, while sickle cell disease alters the shape of red blood cells, often causing severe pain, frequent infections, and life-threatening more concerning is that over half of the affected children were below the age of three, thus, highlighting the desperate need for early screening and preventive interventions."Our findings reveal an urgent public health concern. Early detection through prenatal and newborn screening can dramatically alter disease outcomes," said ,' said Dr. Smita Sudke, Chief of Laboratory, Pune & Rest of Maharashtra at Metropolis and lead author of the DISPARITY AND GENETIC RED FLAGSThe data also reveal regional differences in the spread of these disorders, suggesting that blanket screening policies may not be Northeast had the highest positivity rate at 48.44%, largely due to a high prevalence of Haemoglobin E (HbE). The data also reveal regional differences in the spread of these disorders, suggesting that blanket screening policies may not be enough. Central India saw sickle cell disease dominate, with a positivity rate of 37.36%.Southern states recorded a 34.09% prevalence of various Western and Northern India showed widespread cases of beta-thalassaemia data, say experts, make a compelling case for region-specific screening protocols and stronger integration of genetic testing into routine healthcare services, especially for expectant mothers and young TESTING IS A GAME-CHANGERBeyond identifying the burden, the study highlights the role of molecular diagnostics in catching what traditional tests often such as Next-Generation Sequencing (NGS), Sanger sequencing, and Gap-PCR are transforming how India can detect, diagnose, and manage inherited blood disorders. Beyond identifying the burden, the study highlights the role of molecular diagnostics in catching what traditional tests often miss. () "NGS can look deeply into genes like HBB, HBA1, and HBA2 to detect even the smallest or rarest mutations. This allows for early intervention, even before symptoms show up, and helps guide families in reproductive planning and disease management," explained Dr. Kirti Chadha, Chief Scientific and Innovation Officer at Metropolis earlier nationwide study by Metropolis, involving over 65,000 individuals, also underlined how genetic sequencing can detect both common and rare mutations in haemoglobin genes, essential knowledge in a country where carrier status often goes undiagnosed until it's too FOR PUBLIC AWARENESSIndia is home to nearly 25% of the world's thalassaemia burden. Despite this, genetic testing remains largely out of reach for many, and awareness of these disorders is low, especially in rural experts are calling for national-level policy changes, including:Prenatal and newborn screening programsMandatory genetic counsellingAffordable access to molecular testing, especially in high-prevalence zonesThe message is clear: without early detection and proactive screening, thousands of children will continue to suffer the life-altering effects of preventable genetic India grapples with a rising non-communicable disease burden, inherited blood disorders must not remain in the shadows.
Yahoo
28-04-2025
- Business
- Yahoo
Molecular Diagnostics Market Technologies, Products and Applications Report 2025: North America Leads Molecular Diagnostics Market, While Asia Pacific Emerges as Fastest-Growing Region
Key drivers include the rising need for precise diagnostics in infectious diseases and oncology, with major technologies like PCR and Next-Generation Sequencing (NGS) enhancing efficiency. North America held a 39.2% market share in 2024, while Asia Pacific leads in growth due to escalating healthcare investments. Dominant market segments include reagents, kits, and hospital applications. Molecular Diagnostics Market Dublin, April 22, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors" report has been added to global Molecular Diagnostics market size is estimated at US$18 billion in 2024 and projected to post a CAGR of 10% between 2024 and 2030 to reach US$31.7 billion in 2030. The molecular diagnostics market is growing rapidly, driven by a growing need for faster and more accurate disease detection. With the increasing number of infectious diseases like HIV, tuberculosis, and respiratory infections, healthcare providers rely on molecular tests to quickly identify pathogens and guide treatment. Cancer diagnostics is another major driver, as these tests help detect genetic mutations like BRCA1/2, EGFR, and KRAS, allowing doctors to create personalized treatment plans. Progress in PCR, Next-Generation Sequencing (NGS), and DNA Microarrays made testing more accurate, inexpensive, and widely and private organizations invest considerably in genomic and precision medicine, further supporting innovations. There is also a growing shift toward at-home and point-of-care testing, which is more accessible diagnostics. In addition to infectious diseases and cancer, molecular diagnosis improves early detection of neurological disorders, cardiovascular diseases, and genetic conditions. As the global population rises, the demand for early and targeted treatment increases. Also, new technologies such as AI-driven bioinformatics and portable diagnostic devices are making testing faster and more efficient. Due to its expansion role in drug development and personalized medicine, molecular diagnostics is set to a healthcare revolution and offers better and more adapted treatment for patients globally. Molecular Diagnostics Regional Market AnalysisNorth America leads the global molecular diagnostics market with an estimated 39.2% market share in 2024, driven by technological advancements, robust healthcare infrastructure, and substantial healthcare expenditures. The United States dominates due to significant investments in research and development, supportive regulations, and a high prevalence of chronic diseases such as cancer and cardiovascular issues. Companies benefit from well-established distribution networks and advantageous reimbursement policies, facilitating the swift adoption of innovative diagnostic tools. In contrast, the Asia Pacific region is projected to be the fastest-growing market, with a projected CAGR of 11.3% during the forecast period 2024-2030, driven by increased healthcare funding, population growth, and a rise in disease occurrences. Countries like China, India, and Japan are enhancing healthcare accessibility, while government programs and local manufacturing initiatives contribute to cost-effectiveness. The rising demand for personalized medicine, Next-Generation Sequencing (NGS), and diagnostics powered by AI is propelling the market's growth. The region's commitment to early disease detection and enhanced healthcare infrastructure positions it as a significant contributor to the global molecular diagnostics Diagnostics Market Analysis by ProductThe Reagents and Kits segment dominates the molecular diagnostics market, capturing an estimated 61.3% share in 2024, attributed to their extensive application in testing for infectious diseases, oncology, and genetic diagnostics. Their shorter replacement cycles, flexibility, and vital role in molecular testing ensure consistent demand. Innovations in assay development, increasing awareness for early disease detection, and increased healthcare integration further boost their adoption. Conversely, the Instruments segment is anticipated to record the fastest CAGR of 11.7% from 2024 to 2030, driven by the increasing demand for advanced equipment like PCR machines, NGS systems, and mass spectrometers. The growing use of point-of-care testing, automation, and high-throughput technologies is broadening market prospects, especially in oncology, infectious diseases, and genetic Diagnostics Market Analysis by TechnologyPolymerase Chain Reaction (PCR) segment is the largest technology market, with an estimated 45.2% share in 2024 due to its outstanding accuracy, sensitivity, and versatility in identifying and measuring nucleic acids. PCR continues to be considered the standard for detecting infectious diseases and conducting genetic tests, with innovations such as real-time PCR (qPCR) and digital PCR (dPCR) further improving its capabilities. The increasing use of portable and automated PCR systems in point-of-care environments contributes to its growth. On the other hand, the DNA Sequencing & Next-Generation Sequencing (NGS) segment is anticipated to experience the fastest growth rate with a CAGR of 12.8% during the analysis period 2024-2030, owing to its expanding significance in cancer diagnostics, personalized medicine, and genomics research. The rising need for molecular-targeted therapies and advanced sequencing technologies is driving the use of NGS in clinical and research Diagnostics Market Analysis by ApplicationThe infectious disease diagnostics segment dominates the molecular diagnostics applications market with a 49.3% share in 2024, driven by the increasing incidence of infectious diseases such as respiratory infections, sexually transmitted diseases (STD), and emerging viral outbreaks like COVID-19. The need for quick and accurate diagnostic solutions has spurred the use of PCR and next-generation sequencing (NGS), facilitating precise pathogen identification and effective disease management. Worldwide health initiatives and progress in multiplex PCR and sequencing technologies further bolster market growth. In contrast, the oncology segment is expected to register the fastest growth rate with a CAGR of 12.1%, driven by the rising demand for early cancer detection, personalized treatments, and therapies based on biomarkers, making it a significant contributor to future market Diagnostics Market Report ScopeThis global report on Molecular Diagnostics analyzes the global and regional markets based on product, technology, application, and end-user for the period 2021-2030 with forecasts from 2024 to 2030 in terms of value in US$. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is Metrics Historical Period: 2021-2023 Base Year: 2024 Forecast Period: 2024-2030 Units: Value market in US$ Companies Mentioned: 30+ Key Attributes: Report Attribute Details No. of Pages 340 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $18 Billion Forecasted Market Value (USD) by 2030 $32 Billion Compound Annual Growth Rate 10.0% Regions Covered Global Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE1. INTRODUCTION Molecular Diagnostic Products Reagents and Kits Instruments Software & Services Molecular Diagnostic Technologies Polymerase Chain Reaction (PCR) DNA Sequencing & Next-Generation Sequencing (NGS) Isothermal Nucleic Acid Amplification (INAAT) In Situ Hybridization (ISH) DNA Microarrays Other Technologies (Including Mass Spectrometry (MS), Transcription Mediated Amplification (TMA), CRISPR-based Diagnostics, and Nanotechnology) Molecular Diagnostic Applications Infectious Disease Diagnostics Oncology Testing Genetic Testing Pharmacogenomics Neurological Disorders Diagnostics Cardiovascular Disease Diagnostics Other Applications (Including Reproductive Health & Prenatal Testing, Transplant Diagnostics, Microbiome Analysis, Autoimmune Disease Diagnostics, and others) Molecular Diagnostic End-Users Hospitals and Clinics Diagnostics Laboratories Other End-Users (Including Research Institutes & Academic Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Blood Banks) 2. Key Market Trends3. Key Global Players Abbott Laboratories Agendia NV Agilent Technologies Inc. Becton, Dickinson and Company Biomerieux SA Bio-Rad Laboratories, Inc. Bruker Corporation Danaher Corporation DiaSorin S.p.A DNA Diagnostics Center Exact Sciences Corporation F. Hoffmann-La Roche AG Grifols, S.A. Hologic, Inc. Illumina, Inc. Kaneka Eurogentec S.A. Laboratory Corporation of America Holdings (LabCorp) Merck KGaA Myriad Genetics, Inc. Origene Technologies, Inc. Precipio, Inc. Promega Corporation Qiagen N.V. QuidelOrtho Corporation Revvity, Inc. Savyon Diagnostics Seegene Inc. Siemens Healthineers AG Sorenson Genomics, LLC Sysmex Corporation Thermo Fisher Scientific Inc. 4. Key Business & Technology Trends5. Global Market Overview Molecular Diagnostics Product Market Overview by Global Region Reagents and Kits Instruments Software & Services Molecular Diagnostics Technology Market Overview by Global Region Polymerase Chain Reaction (PCR) DNA Sequencing & Next-Generation Sequencing (NGS) Isothermal Nucleic Acid Amplification (INAAT) In Situ Hybridization (ISH) DNA Microarrays Other Technologies Molecular Diagnostics Application Market Overview by Global Region Infectious Disease Diagnostics Oncology Testing Genetic Testing Pharmacogenomics Neurological Disorders Diagnostics Cardiovascular Disease Diagnostics Other Applications Global Molecular Diagnostics Market Overview by End-User Hospitals and Clinics Diagnostics Laboratories Other End-Users PART B: REGIONAL MARKET PERSPECTIVE Global Molecular Diagnostics Market Overview by Geographic Region PART C: GUIDE TO THE INDUSTRYPART D: ANNEXUREFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Molecular Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
26-04-2025
- Business
- Yahoo
Next-Generation Sequencing (NGS) Data Analysis Market to Hit USD 4.21 Billion by 2032, Driven by Rising Genomic Research and Precision Medicine Initiatives
Rising need for precision medicine, reduced sequencing costs, and worldwide large-scale genomics programs are propelling exponential growth in the NGS Data Analysis Market Austin, April 26, 2025 (GLOBE NEWSWIRE) -- The is valued at USD 791.07 million in 2023, and is predicted to reach USD 4,211.15 million by 2032, expanding at a CAGR of 19.93% from 2024 to 2032. The major drivers behind Next-Generation Sequencing (NGS) Data Analysis Market development are the growing need for personalized healthcare, lowering sequencing costs, and the quick expansion of genomic research programs. Advances in computational biology, big data analytics, and AI-based bioinformatics tools help to further enable faster and more accurate study of vast NGS a Sample Report of Next-generation Sequencing (NGS) Data Analysis Market@ The United States NGS Data Analysis Market value was USD 290.15 million in 2023, predicted to climb to USD 1,509.44 million in 2032 with a CAGR of 19.63% over the forecast period. Strong healthcare infrastructure, significant government support for genomics research, and the presence of premier genomic companies and academic institutions drive the U.S. business. Programs such as the NIH's All of Us Research Program and continuous financing in cancer genomics and rare disease research serve to speed the acceptance of NGS technology and analytical tools all around. The increasing prevalence of complex genetic diseases, cancer, and infectious diseases, high-throughput sequencing technologies. Popular in clinical diagnostics and translational research, NGS enables comprehensive and fairly priced investigations of genomes, transcriptomes, and epigenomes. The industry benefits also from the growing popularity of cloud-based bioinformatics platforms and automated data interpretation tools, which streamline procedures and reduce analysis time. Key Next-generation Sequencing (NGS) Data Analysis Companies Profiled in the Report Illumina, Inc. Thermo Fisher Scientific, Inc. Qiagen N.V. Agilent Technologies F. Hoffmann-La Roche Ltd. 10x Genomics, Inc. PacBio Oxford Nanopore Technologies Bio-Rad Laboratories, Inc. PerkinElmer, Inc. Becton, Dickinson, and Company DNAnexus, Inc. Partek Incorporated Seven Bridges Genomics GeneDx Strand Life Sciences BlueBee Genialis Deep Genomics Illumina-owned Edico Genome Next-generation Sequencing (NGS) Data Analysis Market Report Scope Report Attributes Details Market Size in 2023 US$ 791.07 million Market Size by 2032 US$ 4211.15 million CAGR CAGR of 19.93% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product The NGS Data Analysis Market in 2023 was dominated by the services segment. This segment consists of tertiary and secondary data analysis tools supplied by academic institutions, business service providers, and bioinformatics enterprises. The rise in demand for data analysis outsourcing results from clinical labs and smaller biotech companies without internal bioinformatics capacity. Many companies currently depend on outside knowledge to control raw NGS data, therefore ensuring suitable interpretation for clinical or research purposes. Along with the complexity and volume of NGS databases, the need for scalable, cloud-based solutions and customized service models grows. Highly sought-after are companies offering end-to-end solutions, including quality control and alignment, as well as variant calling and annotation. This has also led to alliances between academic labs, CROs, and hospitals, including specialized data analysis organizations, therefore enhancing market dominance in this segment. By Read Length The 70% of the market share in 2023 was held by the short-read sequencing segment. Short-read technologies such as those presented by Illumina remain the gold standard due to their remarkable accuracy, low cost, and general acceptance in clinical and academic research. Applications in oncology, pharmacogenomics, and infectious disease diagnostics find these technologies very useful for discovering small genetic variants. The analytical pipelines for short-read data are likewise more established and readily available with various open-source tools for variant finding, genome assembly, and transcriptome analysis. Because of scalability, throughput, and established methods in both diagnostics and research environments, short-read technologies still predominate even if long-read sequencing is becoming more and more interesting. By End-Use A 52% of the NGS data analysis market share was held by the academic research segment in 2023. Leading participants in genomic research, colleges, and labs investigate disease paths, population genetics, and therapeutic targets. These facilities demand for robust tools and services for analysis and generate massive volumes of sequencing data. Government subsidies and financial initiatives greatly help the academic support of NGS research. For example, the National Human Genome Research Institute (NHGRI) keeps funding large-scale studies meant to raise demand for data analytics. Interactions between university labs and commercial businesses, which ensure translocation of research into clinical practice and encourage inventiveness, underline even more the primacy of this sector. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ NGS Data Analysis Market Segmentation By Product Services NGS Commercial Software Platform OS/UI Analytical software QC/Pre-processing tools Alignment tools & software DNA sequencing Alignment RNA sequencing Alignment Protein sequencing Alignment others By Workflow Primary Data Analysis Secondary Data Analysis Read mapping Variant alignment & variant calling Tertiary Data Analysis Variant annotation Application-specific data analysis Targeted sequencing/ gene panel Exome RNA sequencing Whole genome sequencing Chip sequencing Others By Mode In-house Data Analysis Outsourced Data Analysis By Read Length Short Read Sequencing Long Read Sequencing Very Long Read Sequencing By End-use Academic Research Clinical Research Hospitals & Clinics Pharma & Biotech Entities Other Users Regional analysis With 48% revenue share, the North America region dominated the NGS data analysis market in 2023. Strong financing from institutions like NIH and NSF, presence of genetic giants like Illumina, Thermo Fisher Scientific, and Agilent Technologies, and strong funding from agencies such as NIH and NSF. Supported by prestigious universities and a well-developed regulatory framework for genomic diagnostics, advanced bioinformatics research is focused particularly in the United States. Asia-Pacific is expected to grow at the fastest CAGR over the forecast period, driven by increasing investments in genomic infrastructure, a vast population base, and an increasing burden of genetic diseases. Funding national genome sequencing projects and building internal bioinformatics expertise are nations such as China, India, and Japan. Government initiatives as GenomeAsia 100K and India's Genomics for Public Health Initiative, raise regional demand for NGS data interpretation. China's great biotechnology drive and the rise of companies like BGI Genomics are turning APAC into a major player in the sector. Rising R&D funding and fast digitization in the healthcare industry define the main direction of development. Recent developments Illumina launched Dragena 4.0, a high-speed, cloud-compatible secondary analysis tool, in January 2024, to expedite whole-genome sequencing activities. Integrating AI-based interpretation tools, Qiagen in December 2023 joined with UK-based Genomics England to increase NGS data processing for cancer of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Data Analysis Tool Adoption, by Type (2023) 5.2 Technology Integration Trends (2023) 5.3 R&D Investments, by Region (2023) 5.4 User Demographics, By User Type and Roles, 2023 5.5 Integration Capabilities 6. Competitive Landscape 7. Next-generation Sequencing (NGS) Data Analysis Market by Product 8. Next-generation Sequencing (NGS) Data Analysis Market by Workflow 9. Next-generation Sequencing (NGS) Data Analysis Market by Mode 10. Next-generation Sequencing (NGS) Data Analysis Market Read Length 11. Next-generation Sequencing (NGS) Data Analysis Market End-use 12. Regional Analysis 13. Company Profiles 14. Use Cases and Best Practices 15. Conclusion Related Reports: Next Generation Sequencing Market Sequencing Market Report DNA Sequencing Market Growth NGS based RNA Sequencing Market Report Single-Cell Sequencing Market Size About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Sign in to access your portfolio
